The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 17,427 |
| Total revenue | - | - | - | -3,033 |
| Research and development | - | - | - | 109,526 |
| General and administrative | - | - | - | 32,775 |
| Total operating expenses | - | - | - | 142,301 |
| Loss from operations | - | - | - | -112,774 |
| Interest income | - | - | - | 5,507 |
| Other income, net | - | - | - | 5,089 |
| Total other income, net | - | - | - | 10,596 |
| Loss before income taxes | - | - | - | -102,178 |
| Provision for income taxes | - | - | - | 140 |
| Net loss | -45,514 | -38,749 | 15,884 | -78,729 |
| Depreciation | 463 | 479 | 555 | 625 |
| Noncash operating lease expense | 972 | 958 | 973 | 1,018 |
| Stock-based compensation | 10,797 | 5,980 | 6,625 | 6,570 |
| Accretion on marketable securities | -1,124 | -768 | -560 | -722 |
| Other, net | -21 | 19 | 1 | 1 |
| Prepaid expenses and other current assets | 2,299 | -350 | 1,652 | 1,110 |
| Other long-term assets | -10 | 13 | -20 | 307 |
| Accounts payable | 1,785 | -1,231 | -344 | -880 |
| Accrued expenses and other liabilities | -8,690 | 4,488 | 1,604 | 1,136 |
| Operating lease liabilities | -781 | -1,193 | -245 | -814 |
| Deferred revenue | - | 0 | -53,811 | -3,181 |
| Net cash used in operating activities | -44,360 | -29,718 | -30,952 | -36,519 |
| Purchase of property and equipment | -2 | 222 | 151 | 624 |
| Sales and maturities of marketable securities | 64,045 | 39,525 | 65,965 | 41,338 |
| Purchases of marketable securities | 54,412 | 175,020 | 18,337 | 23,936 |
| Net cash provided by investing activities | 9,635 | -135,717 | 47,477 | 16,778 |
| Proceeds from issuance of common stock and pre-funded warrants | - | 212,400 | - | - |
| Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under espp | - | 7,012 | 2,541 | 581 |
| Proceeds from at-the-market offerings, net of issuance costs | 62,778 | - | - | - |
| Payment of transaction costs | 537 | 36 | - | - |
| Proceeds from issuance of common stock under stock plans | 17,605 | - | - | - |
| Net cash provided by financing activities | 79,846 | 219,376 | 2,541 | 581 |
| Net change in cash, cash equivalents and restricted cash | 45,121 | 53,941 | 19,066 | -19,160 |
| Cash, cash equivalents and restricted cash, beginning of period | 114,846 | 60,905 | 41,839 | 60,999 |
| Cash, cash equivalents and restricted cash, end of period | 159,967 | 114,846 | 60,905 | 41,839 |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)